124 related articles for article (PubMed ID: 37378903)
1. Survival and Prognostic Factors in Patients With Pancreatic Colloid Carcinoma Compared With Pancreatic Ductal Adenocarcinoma.
Khalil L; Huang Z; Zakka K; Jiang R; Penley M; Alese OB; Shaib WL; Wu C; Behera M; Reid MD; El-Rayes BF; Akce M
Pancreas; 2023 Jan; 52(1):e75-e84. PubMed ID: 37378903
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
3. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma.
Yopp AC; Katabi N; Janakos M; Klimstra DS; D'Angelica MI; DeMatteo RP; Fong Y; Brennan MF; Jarnagin WR; Allen PJ
Ann Surg; 2011 May; 253(5):968-74. PubMed ID: 21422912
[TBL] [Abstract][Full Text] [Related]
4. The Role of Perioperative Chemotherapy in the Management of Colloid Carcinoma of the Pancreas.
Picado O; Dosch AR; Garcia-Buitrago MT; Yakoub D; Dudeja V; Rodgers SE
Pancreas; 2021 Mar; 50(3):306-312. PubMed ID: 33835960
[TBL] [Abstract][Full Text] [Related]
5. IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy.
Kaiser J; Scheifele C; Hinz U; Leonhardt CS; Hank T; Koenig AK; Tjaden C; Hackert T; Bergmann F; Büchler MW; Strobel O
Eur J Surg Oncol; 2022 Jun; 48(6):1309-1320. PubMed ID: 34920899
[TBL] [Abstract][Full Text] [Related]
6. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
7. Intraductal papillary mucinous carcinoma versus pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
Aronsson L; Bengtsson A; Torén W; Andersson R; Ansari D
Int J Surg; 2019 Nov; 71():91-99. PubMed ID: 31546033
[TBL] [Abstract][Full Text] [Related]
8. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study.
Zou Y; Gao S; Yu X; Zhou T; Xie Y; Guo X; An R; Wang X; Zhao T; Chang A; Gao C; Yu J; Hao J
Int J Surg; 2023 Jun; 109(6):1573-1583. PubMed ID: 37132194
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival.
Gavazzi F; Capretti G; Giordano L; Ridolfi C; Spaggiari P; Sollai M; Carrara S; Nappo G; Bozzarelli S; Zerbi A
Dig Liver Dis; 2022 Jun; 54(6):826-833. PubMed ID: 34219044
[TBL] [Abstract][Full Text] [Related]
10. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide register-based study.
Holmberg M; Radkiewicz C; Strömberg C; Öman M; Ghorbani P; Löhr JM; Sparrelid E
Pancreatology; 2023 Jan; 23(1):90-97. PubMed ID: 36522260
[TBL] [Abstract][Full Text] [Related]
11. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms.
Yamada S; Fujii T; Hirakawa A; Takami H; Suenaga M; Hayashi M; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Kodera Y
Pancreas; 2018 Sep; 47(8):974-979. PubMed ID: 30028445
[TBL] [Abstract][Full Text] [Related]
13. Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a prognostic factor in patients with stage IV pancreatic ductal adenocarcinoma.
Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Nakajo M; Maemura K; Arima S; Yoshiura T
Eur Radiol; 2020 Mar; 30(3):1679-1689. PubMed ID: 31728691
[TBL] [Abstract][Full Text] [Related]
14. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Cheng SH; Cheng YJ; Jin ZY; Xue HD
Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
[TBL] [Abstract][Full Text] [Related]
15. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage.
Waters JA; Schnelldorfer T; Aguilar-Saavedra JR; Chen JH; Yiannoutsos CT; Lillemoe KD; Farnell MB; Sarr MG; Schmidt CM
J Am Coll Surg; 2011 Aug; 213(2):275-83. PubMed ID: 21601488
[TBL] [Abstract][Full Text] [Related]
16. Colloid (mucinous noncystic) carcinoma of the pancreas.
Adsay NV; Pierson C; Sarkar F; Abrams J; Weaver D; Conlon KC; Brennan MF; Klimstra DS
Am J Surg Pathol; 2001 Jan; 25(1):26-42. PubMed ID: 11145249
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and meta-analysis comparing the surgical outcomes of invasive intraductal papillary mucinous neoplasms and conventional pancreatic ductal adenocarcinoma.
Koh YX; Chok AY; Zheng HL; Tan CS; Goh BK
Ann Surg Oncol; 2014 Aug; 21(8):2782-800. PubMed ID: 24687151
[TBL] [Abstract][Full Text] [Related]
18. Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matching study.
Shi J; Li X; Wu Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Jun; 50(3):375-382. PubMed ID: 34402250
[TBL] [Abstract][Full Text] [Related]
19. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma.
Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Nagano H; Hidaka S; Kamimura K; Maemura K; Arima S; Yoshiura T
Pancreatology; 2020 Sep; 20(6):1155-1163. PubMed ID: 32800574
[TBL] [Abstract][Full Text] [Related]
20. Validation of Prognostic Radiomic Features From Resectable Pancreatic Ductal Adenocarcinoma in Patients With Advanced Disease Undergoing Chemotherapy.
Salinas-Miranda E; Khalvati F; Namdar K; Deniffel D; Dong X; Abbas E; Wilson JM; O'Kane GM; Knox J; Gallinger S; Haider MA
Can Assoc Radiol J; 2021 Nov; 72(4):605-613. PubMed ID: 33151087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
